Hypertension is more prevalent among HIV-infected individuals than in the general population and contributes to increased cardiovascular risk. The angiotensin II receptor blocker telmisartan is also a partial peroxisome proliferator activated receptor-γ agonist with documented effects on glucose and lipid homeostasis. The aim of this study was to evaluate the antihypertensive and metabolic effects of telmisartan in hypertensive HIV-positive patients.
Methods
A total of 18 HIV-positive men treated with antiretroviral therapy and recently diagnosed with hypertension were administered 80 mg telmisartan daily. Systolic blood pressure (SBP) and diastolic blood pressure (DBP), viroimmunological and metabolic parameters, insulin resistance, C-reactive protein, microalbuminuria, cystatin C and plasma levels of interleukin-18 and endothelin-1 were measured at baseline (T0), 1 month (T1), 3 months (T3) and 6 months (T6).
Results
Treatment with telmisartan not only decreased SBP and DBP levels, but also improved insulin resistance and microalbuminuria by T1. Levels of triglycerides significantly decreased and high-density lipoprotein cholesterol increased at T1, whereas total and low-density lipoprotein cholesterol levels were statistically reduced at T3 and T6. Cystatin C and endothelin-1 showed a significant reduction at T1, whereas interleukin-18 decreased at both T3 and T6.
Conclusions
Telmisartan was effective in reducing blood pressure and improving lipid metabolism and renal function. Reduction of endothelin-1 might be related to an endothelial protective effect. On the basis of these findings, and because of properties unrelated to blood pressure lowering, telmisartan might be the first choice antihypertensive drug for the treatment of HIV-positive patients.
References
1.
KearneyP.M., WheltonM., ReynoldsK., MuntnerP., WheltonP.K., HeJ.Global burden of hypertension: analysis of worldwide data. Lancet2005; 365: 217–223.
2.
PalaciosR., SantosJ., GarciaA.Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naive patients. HIV Med2006; 7: 10–15.
3.
GazzarusoC., BrunoR., GarzanitiA.Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens2003; 21: 1377–1382.
4.
JericóC., KnobelH., MonteroM.Hypertension in HIV-infected patients: prevalence and related factors. Am J Hypertens2005; 18: 1396–1401.
5.
SeabergE.C., MunozA., LuM.Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS2005; 19: 953–960.
6.
ThiébautR., El-SadrW.M., Friis-MollerN.Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antivir Ther2005; 10: 811–823.
7.
NacherM., BasurkoC., VantilckeV.Risk factors for high blood pressure among HIV patients in French Guiana. J Acquir Immune Defic Syndr2008; 48: 629–631.
8.
SharmaA., HolmanS., PittsR., MinkoffH.L., DehovitzJ.A., LazarJ.Peripheral arterial disease in HIV-infected and uninfected women. HIV Med2007; 8: 555–560.
9.
FerrarioC.M.Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research. J Renin Angiotensin Aldosterone Syst2006; 7: 3–14.
10.
YusufS., SleightP., PogueJ., BoschJ., DaviesR., DagenaisG.Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med2000; 342: 145–153.
BensonS.C., PershadsinghH.A., HoC.I.Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension2004; 43: 993–1002.
13.
KurtzT.W.Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta Diabetol2005; 42Suppl 1: S9–S16.
14.
SharpeM., JarvisB., GoaK.L.Telmisartan: a review of its use in hypertension. Drugs2001; 61: 1501–1529.
15.
TakanoH., HasegawaH., ZouY., KomuroI.Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases. Curr Pharm Des2004; 10: 2779–2786.
16.
YamagishiS., TakeuchiM.Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med Hypotheses2005; 64: 476–478.
17.
InoueT., NodeK.Telmisartan as a metabolic sartan for targeting vascular failure. Expert Opin Pharmacother2008; 9: 1397–1406.
18.
VitaleC., MercuroG., CastiglioniC.Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol2005; 4: 6.
19.
MiuraY., YamamotoN., TsunekawaS.Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care2005; 28: 757–758.
20.
ShimabukuroM., TanakaH., ShimabukuroT.Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens2007; 25: 841–848.
21.
SanchezR.A., MasnattaL.D., PesineyC., FischerP., RamirezA.J.Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives. J Hypertens2008; 26: 2393–2398.
22.
MakinoH., HanedaM., BabazonoT.Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care2007; 30: 1577–1578.
23.
ManciaG., De BackerG., DominiczakA.[ESH/ ESC 2007 Guidelines for the management of arterial hypertension]. Rev Esp Cardiol2007; 60: 968e1–94. Spanish.
24.
LawM.G., Friis-MollerN., El-SadrW.M.The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med2006; 7: 218–230.
25.
KannelW.B., FeinleibM., McNamaraP.M., GarrisonR.J., CastelliW P.An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol1979; 110: 281–290.
26.
CoreshJ., AstorB.C., McQuillanG.Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis2002; 39: 920–929.
27.
PeriardD., CavassiniM., TaffeP.High prevalence of peripheral arterial disease in HIV-infected persons. Clin Infect Dis2008; 46: 761–767.
28.
UcciferriC., MancinoP., VecchietJ., FalascaK.Beneficial effects of telmisartan in an HIV+ diabetic insulin-dependent patient. Int J Immunopathol Pharmacol2009; 22: 853–857.
29.
ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, et al.Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med2008; 358: 1547–1559.
30.
ZouZ., XiG.L., YuanH.B., ZhuQ.F., ShiX.Y.Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials. J Hum Hypertens2009; 23: 339–349.
31.
SharmaA.M., DavidsonJ., KovalS., LacourciereY.Telmisartan/hydrochlorothiazide versus valsartan/ hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. Cardiovasc Diabetol2007; 6: 28.
32.
HonjoS., NichiY., WadaY., HamamotoY., KoshiyamaH.Possible beneficial effect of telmisartan on glycemic control in diabetic subjects. Diabetes Care2005; 28: 498.
33.
FalascaK., UcciferriC., ManzoliL.Metabolic syndrome and cardiovascular risk in HIV-infected patients with lipodystrophy. Int J Immunopathol Pharmacol2007; 20: 519–527.
ShlipakM.G., SarnakM.J., KatzR.Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med2005; 352: 2049–2060.
36.
MuntnerP., MannD., WinstonJ., BansilalS., FarkouhM.E.Serum cystatin C and increased coronary heart disease prevalence in US adults without chronic kidney disease. Am J Cardiol2008; 102: 54–57.
37.
ArpegårdJ., OstergrenJ., de FaireU., HanssonL.O., SvenssonP.Cystatin C – a marker of peripheral atherosclerotic disease?Atherosclerosis2008; 199: 397–401.
38.
OddenM.C., ScherzerR., BacchettiP.Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study. Arch Intern Med2007; 167: 2213–2219.
39.
FalascaK., UcciferriC., MancinoP.Cystatin C, adipokines and cardiovascular risk In HIV infected patients. Curr HIV Res2010; 8: 405–410.
40.
SchraderJ., LudersS., KulschewskiA.Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study)*. J Hypertens2006; 24: 541–548.
41.
BaekkenM., OsI., SandvikL., OektedalenO.Microalbuminuria associated with indicators of inflammatory activity in an HIV-positive population. Nephrol Dial Transplant2008; 23: 3130–3137.
42.
CianchettiS., Del FiorentinoA., ColognatoR., Di StefanoR., FranzoniF., PedrinelliR.Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis2008; 198: 22–28.
43.
SchmiederR.E., DellesC., MimranA., FauvelJ.P., RuilopeL.M.Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care2007; 30: 1351–1356.
44.
YanagisawaM., KuriharaH., KimuraS.A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature1988; 332: 411–415.
DeleriveP., Martin-NizardF., ChinettiG.Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res1999; 85: 394–402.
48.
FukunagaY., ItohH., DoiK.Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides. Atherosclerosis2001; 158: 113–119.
49.
WangT.D., ChenW.J., ChengW.C., LinJ.W., ChenM.F., LeeY.T.Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome. Am J Cardiol2006; 98: 1057–1062.
50.
SipahiI., DebanneS.M., RowlandD.Y., SimonD.I., FangJ.C.Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol2010; 11: 627–636.
